The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC

Stefan Frantz, Ines Falcao-Pires, Jean-Luc Balligand, Johann Bauersachs, Dirk Brutsaert, Michele Ciccarelli, Dana Dawson, Leon J de Windt, Mauro Giacca, Nazha Hamdani, Denise Hilfiker-Kleiner, Emilio Hirsch, Adelino Leite-Moreira, Manuel Mayr, Thomas Thum, Carlo G Tocchetti, Jolanda van der Velden, Gilda Varricchi, Stephane Heymans

Research output: Contribution to journalReview article

19 Citations (Scopus)
5 Downloads (Pure)

Abstract

Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF overlapping mechanisms occur in different aetiologies.

Original languageEnglish
Pages (from-to)445-459
Number of pages15
JournalEuropean Journal of Heart Failure
Volume20
Issue number3
Early online date15 Jan 2018
DOIs
Publication statusPublished - Mar 2018

Fingerprint

Cardiology
Cardiomyopathies
Immune System
Heart Failure
Peripartum Period
Poisons

Keywords

  • Journal Article
  • Review

Cite this

The innate immune system in chronic cardiomyopathy : a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. / Frantz, Stefan; Falcao-Pires, Ines; Balligand, Jean-Luc; Bauersachs, Johann; Brutsaert, Dirk; Ciccarelli, Michele; Dawson, Dana; de Windt, Leon J; Giacca, Mauro; Hamdani, Nazha; Hilfiker-Kleiner, Denise; Hirsch, Emilio; Leite-Moreira, Adelino; Mayr, Manuel; Thum, Thomas; Tocchetti, Carlo G; van der Velden, Jolanda; Varricchi, Gilda; Heymans, Stephane.

In: European Journal of Heart Failure, Vol. 20, No. 3, 03.2018, p. 445-459.

Research output: Contribution to journalReview article

Frantz, S, Falcao-Pires, I, Balligand, J-L, Bauersachs, J, Brutsaert, D, Ciccarelli, M, Dawson, D, de Windt, LJ, Giacca, M, Hamdani, N, Hilfiker-Kleiner, D, Hirsch, E, Leite-Moreira, A, Mayr, M, Thum, T, Tocchetti, CG, van der Velden, J, Varricchi, G & Heymans, S 2018, 'The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC', European Journal of Heart Failure, vol. 20, no. 3, pp. 445-459. https://doi.org/10.1002/ejhf.1138
Frantz, Stefan ; Falcao-Pires, Ines ; Balligand, Jean-Luc ; Bauersachs, Johann ; Brutsaert, Dirk ; Ciccarelli, Michele ; Dawson, Dana ; de Windt, Leon J ; Giacca, Mauro ; Hamdani, Nazha ; Hilfiker-Kleiner, Denise ; Hirsch, Emilio ; Leite-Moreira, Adelino ; Mayr, Manuel ; Thum, Thomas ; Tocchetti, Carlo G ; van der Velden, Jolanda ; Varricchi, Gilda ; Heymans, Stephane. / The innate immune system in chronic cardiomyopathy : a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. In: European Journal of Heart Failure. 2018 ; Vol. 20, No. 3. pp. 445-459.
@article{55341100434c40d0b9f3343dd2cc5954,
title = "The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC",
abstract = "Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF overlapping mechanisms occur in different aetiologies.",
keywords = "Journal Article, Review",
author = "Stefan Frantz and Ines Falcao-Pires and Jean-Luc Balligand and Johann Bauersachs and Dirk Brutsaert and Michele Ciccarelli and Dana Dawson and {de Windt}, {Leon J} and Mauro Giacca and Nazha Hamdani and Denise Hilfiker-Kleiner and Emilio Hirsch and Adelino Leite-Moreira and Manuel Mayr and Thomas Thum and Tocchetti, {Carlo G} and {van der Velden}, Jolanda and Gilda Varricchi and Stephane Heymans",
note = "Funded by Regione Campania CISI-Lab European Union Commission's Seventh Framework . Grant Number: 305507, 602904 FP7-Health-2013-Innovations-1. Grant Number: 602156 FWO Flanders, Belgium. Grant Number: FWO G080014 N European Union Horizon2020. Grant Number: UE LSHM-CT-05-018833, FNRS PDR T.0144.13 Bundesministerium f{\"u}r Bildung und Forschung. Grant Number: BMBF01 EO1004 Deutsche Forschungsgemeinschaft. Grant Number: SFB688 TP A10",
year = "2018",
month = "3",
doi = "10.1002/ejhf.1138",
language = "English",
volume = "20",
pages = "445--459",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - The innate immune system in chronic cardiomyopathy

T2 - a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC

AU - Frantz, Stefan

AU - Falcao-Pires, Ines

AU - Balligand, Jean-Luc

AU - Bauersachs, Johann

AU - Brutsaert, Dirk

AU - Ciccarelli, Michele

AU - Dawson, Dana

AU - de Windt, Leon J

AU - Giacca, Mauro

AU - Hamdani, Nazha

AU - Hilfiker-Kleiner, Denise

AU - Hirsch, Emilio

AU - Leite-Moreira, Adelino

AU - Mayr, Manuel

AU - Thum, Thomas

AU - Tocchetti, Carlo G

AU - van der Velden, Jolanda

AU - Varricchi, Gilda

AU - Heymans, Stephane

N1 - Funded by Regione Campania CISI-Lab European Union Commission's Seventh Framework . Grant Number: 305507, 602904 FP7-Health-2013-Innovations-1. Grant Number: 602156 FWO Flanders, Belgium. Grant Number: FWO G080014 N European Union Horizon2020. Grant Number: UE LSHM-CT-05-018833, FNRS PDR T.0144.13 Bundesministerium für Bildung und Forschung. Grant Number: BMBF01 EO1004 Deutsche Forschungsgemeinschaft. Grant Number: SFB688 TP A10

PY - 2018/3

Y1 - 2018/3

N2 - Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF overlapping mechanisms occur in different aetiologies.

AB - Activation of the immune system in heart failure (HF) has been recognized for over 20 years. Initially, experimental studies demonstrated a maladaptive role of the immune system. However, several phase III trials failed to show beneficial effects in HF with therapies directed against an immune activation. Preclinical studies today describe positive and negative effects of immune activation in HF. These different effects depend on timing and aetiology of HF. Therefore, herein we give a detailed review on immune mechanisms and their importance for the development of HF with a special focus on commonalities and differences between different forms of cardiomyopathies. The role of the immune system in ischaemic, hypertensive, diabetic, toxic, viral, genetic, peripartum, and autoimmune cardiomyopathy is discussed in depth. Overall, initial damage to the heart leads to disease specific activation of the immune system whereas in the chronic phase of HF overlapping mechanisms occur in different aetiologies.

KW - Journal Article

KW - Review

U2 - 10.1002/ejhf.1138

DO - 10.1002/ejhf.1138

M3 - Review article

C2 - 29333691

VL - 20

SP - 445

EP - 459

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 3

ER -